Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) saw a large decline in short interest during the month of October. As of October 30th, there was short interest totaling 306 shares, a decline of 65.8% from the October 15th total of 896 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 838 shares, the short-interest ratio is presently 0.4 days.
Amplify Weight Loss Drug & Treatment ETF Stock Down 1.1%
Shares of THNR stock opened at $26.02 on Friday. The company’s fifty day simple moving average is $25.34 and its two-hundred day simple moving average is $25.33. Amplify Weight Loss Drug & Treatment ETF has a 52 week low of $23.40 and a 52 week high of $27.94. The stock has a market cap of $5.20 million, a P/E ratio of 22.59 and a beta of 0.40.
Amplify Weight Loss Drug & Treatment ETF Company Profile
The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.
See Also
- Five stocks we like better than Amplify Weight Loss Drug & Treatment ETF
- Golden Dome’s $185 Billion Question: Who Actually Gets Paid?
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
Receive News & Ratings for Amplify Weight Loss Drug & Treatment ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amplify Weight Loss Drug & Treatment ETF and related companies with MarketBeat.com's FREE daily email newsletter.
